Aumolertinib
Phase 3Small molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.Aumolertinib is one of 76 small molecule programs targeting Lung Cancer. It is currently in Phase 3.
2
Indications
12
Total Trials
6
Active Trials
75
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Retevmo
Eli LillyPhase 3
Leqembi
EisaiPhase 3
Krazati
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Aumolertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer6 trials
Show 3 more trials
A Randomized, Open-label, Multicenter, Phase III Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib as First-line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutations
Active, not recruiting·
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07183189·582 enrolled
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·NCT07183189·582 enrolledNeoadjuvant1 trial
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
Unknown status·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 2·NCT05946460·22 enrolled
Tics1 trial
Oral1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aumolertinib. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details